Fundraise

COFIDES puts €11M into stroke-tech firm Anaconda Biomed's $56M round

What's the deal? COFIDESDealroom has a profile for this one. Try Dealroom → has invested €11 million in Anaconda Biomed, a Barcelona-area medical technology company developing devices to treat ischaemic stroke. The investment, made through Spain's FOCO co-investment fund, is part of a larger Series E round worth €49 million led by Omega FundsDealroom has a profile for this one. Try Dealroom →.

Who else is in? Existing backers AsabysDealroom has a profile for this one. Try Dealroom →, Ysios CapitalDealroom has a profile for this one. Try Dealroom →, and CDTI, through its Innvierte program, also took part. Omega Funds and most of the syndicate have supported the company through earlier rounds.

What's the endgame? Anaconda Biomed builds the ANA Funnel Catheter, a self-expanding device for mechanical thrombectomy that captures and removes blood clots while temporarily halting blood flow. The funding will mainly go towards completing ATHENA, a 327-patient pivotal trial, with product development and regulatory approvals to follow.

Why now? The company's ANA5 model earned its CE mark in June 2025, opening commercial distribution in Europe. In the US, the device remains investigational and limited to clinical trials. ATHENA is expected to finish in 2027, after which the firm aims to begin marketing in both regions.

Founded in 2015 as a spin-off of Barcelona's Vall d'Hebron Research InstituteDealroom has a profile for this one. Try Dealroom →, Anaconda keeps its production near the city, in Sant Quirze del Vallès, and reports a presence in Marin, California.

What could go wrong? The round backs a clinical-stage company, not a proven commercial one. Anaconda still needs to deliver trial and regulatory milestones, and it enters a competitive field where established thrombectomy players are investing in their own devices.

What they said: "The support of this leading group of investors reflects the growing confidence in our technology platform," said Trent Reutiman, chief executive officer of Anaconda Biomed.

The signal: The deal shows European health deep tech reaching its most expensive stage — a US pivotal trial — with a hospital-research origin and manufacturing kept at home. FOCO, financed by the EU's NextGenerationEU programme, pairs public capital with foreign co-investors to back Spanish companies tied to the digital and green transitions.

Read more: webcapitalriesgo.com

Image credit: Generated with Gemini

More top stories